Alcoholic liver disease medical therapy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
m (Bot: Removing from Primary care)
 
(4 intermediate revisions by 2 users not shown)
Line 9: Line 9:
===General Therapy===
===General Therapy===


General therapy for [[alcoholic liver disease]] includes:<ref name="pmid19745759">{{cite journal |vauthors=Sofair AN, Barry V, Manos MM, Thomas A, Zaman A, Terrault NA, Murphy RC, Stabach N, Huie S, Van Ness G, Bell BP, Bialek S |title=The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from population-based surveillance |journal=J. Clin. Gastroenterol. |volume=44 |issue=4 |pages=301–7 |year=2010 |pmid=19745759 |doi=10.1097/MCG.0b013e3181b3f760 |url=}}</ref><ref name="pmid19788058">{{cite journal |vauthors=Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B |title=Deaths: final data for 2006 |journal=Natl Vital Stat Rep |volume=57 |issue=14 |pages=1–134 |year=2009 |pmid=19788058 |doi= |url=}}</ref><ref name="pmid19489992">{{cite journal |vauthors=Kaner EF, Dickinson HO, Beyer F, Pienaar E, Schlesinger C, Campbell F, Saunders JB, Burnand B, Heather N |title=The effectiveness of brief alcohol interventions in primary care settings: a systematic review |journal=Drug Alcohol Rev |volume=28 |issue=3 |pages=301–23 |year=2009 |pmid=19489992 |doi=10.1111/j.1465-3362.2009.00071.x |url=}}</ref><ref name="pmid8925349">{{cite journal |vauthors=Moos RH, King MJ, Patterson MA |title=Outcomes of residential treatment of substance abuse in hospital- and community-based programs |journal=Psychiatr Serv |volume=47 |issue=1 |pages=68–74 |year=1996 |pmid=8925349 |doi=10.1176/ps.47.1.68 |url=}}</ref><ref name="pmid15200577">{{cite journal |vauthors=Bouza C, Angeles M, Magro A, Muñoz A, Amate JM |title=Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review |journal=Addiction |volume=99 |issue=7 |pages=811–28 |year=2004 |pmid=15200577 |doi=10.1111/j.1360-0443.2004.00763.x |url=}}</ref><ref name="pmid10208148">{{cite journal |vauthors=Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT |title=Pharmacological treatment of alcohol dependence: a review of the evidence |journal=JAMA |volume=281 |issue=14 |pages=1318–25 |year=1999 |pmid=10208148 |doi= |url=}}</ref><ref name="pmid19630744">{{cite journal |vauthors=Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM |title=Review of topiramate: an antiepileptic for the treatment of alcohol dependence |journal=Curr Drug Abuse Rev |volume=2 |issue=2 |pages=135–42 |year=2009 |pmid=19630744 |doi= |url=}}</ref><ref name="pmid18068515">{{cite journal |vauthors=Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G |title=Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study |journal=Lancet |volume=370 |issue=9603 |pages=1915–22 |year=2007 |pmid=18068515 |doi=10.1016/S0140-6736(07)61814-5 |url=}}</ref><ref name="pmid7672043">{{cite journal |vauthors=Corrao G, Lepore AR, Torchio P, Valenti M, Galatola G, D'Amicis A, Aricó S, di Orio F |title=The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Provincial Group for the Study of Chronic Liver Disease |journal=Eur. J. Epidemiol. |volume=10 |issue=6 |pages=657–64 |year=1994 |pmid=7672043 |doi= |url=}}</ref><ref name="pmid1476147">{{cite journal |vauthors=Klatsky AL, Armstrong MA |title=Alcohol, smoking, coffee, and cirrhosis |journal=Am. J. Epidemiol. |volume=136 |issue=10 |pages=1248–57 |year=1992 |pmid=1476147 |doi= |url=}}</ref><ref name="pmid8985274">{{cite journal |vauthors=Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC |title=Excess weight risk factor for alcoholic liver disease |journal=Hepatology |volume=25 |issue=1 |pages=108–11 |year=1997 |pmid=8985274 |doi=10.1002/hep.510250120 |url=}}</ref><ref name="pmid15349806">{{cite journal |vauthors=Halsted CH |title=Nutrition and alcoholic liver disease |journal=Semin. Liver Dis. |volume=24 |issue=3 |pages=289–304 |year=2004 |pmid=15349806 |doi=10.1055/s-2004-832941 |url=}}</ref><ref name="pmid16099027">{{cite journal |vauthors=Kang YJ, Zhou Z |title=Zinc prevention and treatment of alcoholic liver disease |journal=Mol. Aspects Med. |volume=26 |issue=4-5 |pages=391–404 |year=2005 |pmid=16099027 |doi=10.1016/j.mam.2005.07.002 |url=}}</ref><ref name="pmid9820369">{{cite journal |vauthors=McCullough AJ, O'Connor JF |title=Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology |journal=Am. J. Gastroenterol. |volume=93 |issue=11 |pages=2022–36 |year=1998 |pmid=9820369 |doi=10.1111/j.1572-0241.1998.00587.x |url=}}</ref>
General therapy for alcoholic liver disease includes:<ref name="pmid19745759">{{cite journal |vauthors=Sofair AN, Barry V, Manos MM, Thomas A, Zaman A, Terrault NA, Murphy RC, Stabach N, Huie S, Van Ness G, Bell BP, Bialek S |title=The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from population-based surveillance |journal=J. Clin. Gastroenterol. |volume=44 |issue=4 |pages=301–7 |year=2010 |pmid=19745759 |doi=10.1097/MCG.0b013e3181b3f760 |url=}}</ref><ref name="pmid19788058">{{cite journal |vauthors=Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B |title=Deaths: final data for 2006 |journal=Natl Vital Stat Rep |volume=57 |issue=14 |pages=1–134 |year=2009 |pmid=19788058 |doi= |url=}}</ref><ref name="pmid19489992">{{cite journal |vauthors=Kaner EF, Dickinson HO, Beyer F, Pienaar E, Schlesinger C, Campbell F, Saunders JB, Burnand B, Heather N |title=The effectiveness of brief alcohol interventions in primary care settings: a systematic review |journal=Drug Alcohol Rev |volume=28 |issue=3 |pages=301–23 |year=2009 |pmid=19489992 |doi=10.1111/j.1465-3362.2009.00071.x |url=}}</ref><ref name="pmid8925349">{{cite journal |vauthors=Moos RH, King MJ, Patterson MA |title=Outcomes of residential treatment of substance abuse in hospital- and community-based programs |journal=Psychiatr Serv |volume=47 |issue=1 |pages=68–74 |year=1996 |pmid=8925349 |doi=10.1176/ps.47.1.68 |url=}}</ref><ref name="pmid15200577">{{cite journal |vauthors=Bouza C, Angeles M, Magro A, Muñoz A, Amate JM |title=Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review |journal=Addiction |volume=99 |issue=7 |pages=811–28 |year=2004 |pmid=15200577 |doi=10.1111/j.1360-0443.2004.00763.x |url=}}</ref><ref name="pmid10208148">{{cite journal |vauthors=Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT |title=Pharmacological treatment of alcohol dependence: a review of the evidence |journal=JAMA |volume=281 |issue=14 |pages=1318–25 |year=1999 |pmid=10208148 |doi= |url=}}</ref><ref name="pmid19630744">{{cite journal |vauthors=Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM |title=Review of topiramate: an antiepileptic for the treatment of alcohol dependence |journal=Curr Drug Abuse Rev |volume=2 |issue=2 |pages=135–42 |year=2009 |pmid=19630744 |doi= |url=}}</ref><ref name="pmid18068515">{{cite journal |vauthors=Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G |title=Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study |journal=Lancet |volume=370 |issue=9603 |pages=1915–22 |year=2007 |pmid=18068515 |doi=10.1016/S0140-6736(07)61814-5 |url=}}</ref><ref name="pmid7672043">{{cite journal |vauthors=Corrao G, Lepore AR, Torchio P, Valenti M, Galatola G, D'Amicis A, Aricó S, di Orio F |title=The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Provincial Group for the Study of Chronic Liver Disease |journal=Eur. J. Epidemiol. |volume=10 |issue=6 |pages=657–64 |year=1994 |pmid=7672043 |doi= |url=}}</ref><ref name="pmid1476147">{{cite journal |vauthors=Klatsky AL, Armstrong MA |title=Alcohol, smoking, coffee, and cirrhosis |journal=Am. J. Epidemiol. |volume=136 |issue=10 |pages=1248–57 |year=1992 |pmid=1476147 |doi= |url=}}</ref><ref name="pmid8985274">{{cite journal |vauthors=Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC |title=Excess weight risk factor for alcoholic liver disease |journal=Hepatology |volume=25 |issue=1 |pages=108–11 |year=1997 |pmid=8985274 |doi=10.1002/hep.510250120 |url=}}</ref><ref name="pmid15349806">{{cite journal |vauthors=Halsted CH |title=Nutrition and alcoholic liver disease |journal=Semin. Liver Dis. |volume=24 |issue=3 |pages=289–304 |year=2004 |pmid=15349806 |doi=10.1055/s-2004-832941 |url=}}</ref><ref name="pmid16099027">{{cite journal |vauthors=Kang YJ, Zhou Z |title=Zinc prevention and treatment of alcoholic liver disease |journal=Mol. Aspects Med. |volume=26 |issue=4-5 |pages=391–404 |year=2005 |pmid=16099027 |doi=10.1016/j.mam.2005.07.002 |url=}}</ref><ref name="pmid9820369">{{cite journal |vauthors=McCullough AJ, O'Connor JF |title=Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology |journal=Am. J. Gastroenterol. |volume=93 |issue=11 |pages=2022–36 |year=1998 |pmid=9820369 |doi=10.1111/j.1572-0241.1998.00587.x |url=}}</ref>
*Abstinence from [[alcohol]] has been shown to lead to resolution of [[hepatic steatosis]] and slow the progression of alcoholic [[fibrosis]], [[cirrhosis]] and decompensated [[liver failure]].
*Abstinence from [[alcohol]] has been shown to lead to resolution of [[hepatic steatosis]] and slow the progression of alcoholic [[fibrosis]], [[cirrhosis]] and decompensated [[liver failure]].
*[[Counseling]] and family support during [[alcohol]] abstinence
*[[Counseling]] and family support during [[alcohol]] abstinence.
*Assessment and treatment of underlying [[psychiatric]] conditions
*Assessment and treatment of underlying [[psychiatric]] conditions.
*[[Naltrexone]] or [[acamprosate]] to reduce relapse
*[[Naltrexone]] or [[acamprosate]] to reduce relapse.
*[[Disulfiram]], under supervision and [[topiramate]] for decreasing craving and [[withdrawal symptoms]] have also been approved to be used for treating [[alcohol dependence]]
*[[Disulfiram]], under supervision and [[topiramate]] for decreasing craving and [[withdrawal symptoms]] have also been approved to be used for treating [[alcohol dependence]].
*[[Baclofen]] has been shown to treat [[alcohol dependence]] in patients who are actively consuming [[alcohol]] and have [[liver cirrhosis]]
*[[Baclofen]] has been shown to treat [[alcohol dependence]] in patients who are actively consuming [[alcohol]] and have [[liver cirrhosis]].
*[[Smoking cessation]] and [[weight loss]] where indicated is very important in the treatment of [[alcoholic liver disease]] as they are both independent risk factors for development of [[hepatic fibrosis]] and [[cirrhosis]]
*[[Smoking cessation]] and [[weight loss]] where indicated is very important in the treatment of alcoholic liver disease as they are both independent risk factors for development of [[hepatic fibrosis]] and [[cirrhosis]].
*Nutritional support - Adequate amounts of [[Carbohydrate|carbohydrates]] and [[calories]] as alcoholics are commonly [[malnourished]]. This prevents endogenous [[protein]] [[catabolism]], and [[hypoglycemia]]. Administration of [[thiamine]] is important with [[glucose]] supplements. This is so because [[glucose]] administration increases [[vitamin B1]] consumption and [[vitamin B1]] deficiency may lead to [[Wernicke–Korsakoff syndrome]].
*Nutritional support - Adequate amounts of [[Carbohydrate|carbohydrates]] and [[calories]] as alcoholics are commonly [[malnourished]]. This prevents endogenous [[protein]] [[catabolism]], and [[hypoglycemia]]. Administration of [[thiamine]] is important with [[glucose]] supplements. This is so because [[glucose]] administration increases [[vitamin B1]] consumption and [[vitamin B1]] deficiency may lead to [[Wernicke–Korsakoff syndrome]].
*[[Folic acid]], [[thiamine]], [[vitamin B6]], [[vitamin A]] and [[zinc]] supplements are recommended.
*[[Folic acid]], [[thiamine]], [[vitamin B6]], [[vitamin A]] and [[zinc]] supplements are recommended.
*Nutritional support guidelines; 1.2–1.5 g/kg of protein and 35–40 kcal/kg of body weight per day in patients suffering from [[alcoholic liver disease]]
*Nutritional support guidelines; 1.2–1.5 g/kg of protein and 35–40 kcal/kg of body weight per day in patients suffering from alcoholic liver disease.


===Drug therapy===
===Pharmacotherapy===
====Alcoholic hepatitis====
====Alcoholic hepatitis====
* '''Glucocorticoids'''<ref name="pmid19389182">{{cite journal |vauthors=Addolorato G, Russell M, Albano E, Haber PS, Wands JR, Leggio L |title=Understanding and treating patients with alcoholic cirrhosis: an update |journal=Alcohol. Clin. Exp. Res. |volume=33 |issue=7 |pages=1136–44 |year=2009 |pmid=19389182 |doi=10.1111/j.1530-0277.2009.00956.x |url=}}</ref><ref name="pmid11943428">{{cite journal |vauthors=Christensen E |title=Alcoholic hepatitis--glucocorticosteroids or not? |journal=J. Hepatol. |volume=36 |issue=4 |pages=547–8 |year=2002 |pmid=11943428 |doi= |url=}}</ref><ref name="pmid1531090">{{cite journal |vauthors=Ramond MJ, Poynard T, Rueff B, Mathurin P, Théodore C, Chaput JC, Benhamou JP |title=A randomized trial of prednisolone in patients with severe alcoholic hepatitis |journal=N. Engl. J. Med. |volume=326 |issue=8 |pages=507–12 |year=1992 |pmid=1531090 |doi=10.1056/NEJM199202203260802 |url=}}</ref><ref name="pmid2648927">{{cite journal |vauthors=Carithers RL, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, Maddrey WC |title=Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial |journal=Ann. Intern. Med. |volume=110 |issue=9 |pages=685–90 |year=1989 |pmid=2648927 |doi= |url=}}</ref><ref name="pmid352788">{{cite journal |vauthors=Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI |title=Corticosteroid therapy of alcoholic hepatitis |journal=Gastroenterology |volume=75 |issue=2 |pages=193–9 |year=1978 |pmid=352788 |doi= |url=}}</ref><ref name="pmid18363896">{{cite journal |vauthors=Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C |title=Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials |journal=Aliment. Pharmacol. Ther. |volume=27 |issue=12 |pages=1167–78 |year=2008 |pmid=18363896 |doi=10.1111/j.1365-2036.2008.03685.x |url=}}</ref><ref name="pmid16503078">{{cite journal |vauthors=O'Shea R, McCullough AJ |title=Steroids or cocktails for alcoholic hepatitis |journal=J. Hepatol. |volume=44 |issue=4 |pages=633–6 |year=2006 |pmid=16503078 |doi=10.1016/j.jhep.2006.01.011 |url=}}</ref><ref name="urlLilleModel">{{cite web |url=http://www.lillemodel.com |title=LilleModel |format= |work= |accessdate=}}</ref>
* '''Glucocorticoids'''<ref name="pmid19389182">{{cite journal |vauthors=Addolorato G, Russell M, Albano E, Haber PS, Wands JR, Leggio L |title=Understanding and treating patients with alcoholic cirrhosis: an update |journal=Alcohol. Clin. Exp. Res. |volume=33 |issue=7 |pages=1136–44 |year=2009 |pmid=19389182 |doi=10.1111/j.1530-0277.2009.00956.x |url=}}</ref><ref name="pmid11943428">{{cite journal |vauthors=Christensen E |title=Alcoholic hepatitis--glucocorticosteroids or not? |journal=J. Hepatol. |volume=36 |issue=4 |pages=547–8 |year=2002 |pmid=11943428 |doi= |url=}}</ref><ref name="pmid1531090">{{cite journal |vauthors=Ramond MJ, Poynard T, Rueff B, Mathurin P, Théodore C, Chaput JC, Benhamou JP |title=A randomized trial of prednisolone in patients with severe alcoholic hepatitis |journal=N. Engl. J. Med. |volume=326 |issue=8 |pages=507–12 |year=1992 |pmid=1531090 |doi=10.1056/NEJM199202203260802 |url=}}</ref><ref name="pmid2648927">{{cite journal |vauthors=Carithers RL, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, Maddrey WC |title=Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial |journal=Ann. Intern. Med. |volume=110 |issue=9 |pages=685–90 |year=1989 |pmid=2648927 |doi= |url=}}</ref><ref name="pmid352788">{{cite journal |vauthors=Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI |title=Corticosteroid therapy of alcoholic hepatitis |journal=Gastroenterology |volume=75 |issue=2 |pages=193–9 |year=1978 |pmid=352788 |doi= |url=}}</ref><ref name="pmid18363896">{{cite journal |vauthors=Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C |title=Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials |journal=Aliment. Pharmacol. Ther. |volume=27 |issue=12 |pages=1167–78 |year=2008 |pmid=18363896 |doi=10.1111/j.1365-2036.2008.03685.x |url=}}</ref><ref name="pmid16503078">{{cite journal |vauthors=O'Shea R, McCullough AJ |title=Steroids or cocktails for alcoholic hepatitis |journal=J. Hepatol. |volume=44 |issue=4 |pages=633–6 |year=2006 |pmid=16503078 |doi=10.1016/j.jhep.2006.01.011 |url=}}</ref><ref name="urlLilleModel">{{cite web |url=http://www.lillemodel.com |title=LilleModel |format= |work= |accessdate=}}</ref>
**Beneficial in patients with [[hepatic encephalopathy]], Maddrey's discriminant function score ≥32, or a [[MELD Score|MELD]] score ≥21
**Beneficial in patients with [[hepatic encephalopathy]], Maddrey's discriminant function score ≥32, or a [[MELD Score|MELD]] score ≥21.
**Decreases short term [[mortality]]
**Decreases short term [[mortality]].
**Usually given for 1 month
**Usually given for 1 month.
**Serum [[bilirubin]] is used as a predictor for treatment success. Failure of the [[Bilirubin|serum bilirubin]] level to decline after 7 days of treatment predicts poor prognosis
**Serum [[bilirubin]] is used as a predictor for treatment success. Failure of the [[Bilirubin|serum bilirubin]] level to decline after 7 days of treatment predicts poor prognosis.
**Another predictor of treatment is '''Lille model''' comprising, [[age]], serum [[creatinine]], serum [[albumin]], [[prothrombin time]] (or INR), serum [[bilirubin]] on admission, and [[serum bilirubin]] on day 7
**Another predictor of treatment is '''Lille model''' comprising, [[age]], serum [[creatinine]], serum [[albumin]], [[prothrombin time]] (or INR), serum [[bilirubin]] on admission, and [[serum bilirubin]] on day 7.
**Contraindicated in the presence of [[sepsis]], [[hepatorenal syndrome]], [[chronic hepatitis B]] virus infection and [[gastrointestinal bleeding]]
**Contraindicated in the presence of [[sepsis]], [[hepatorenal syndrome]], [[chronic hepatitis B]] virus infection and [[gastrointestinal bleeding]].
* '''Pentoxifylline'''<ref name="pmid11113085">{{cite journal |vauthors=Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O |title=Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial |journal=Gastroenterology |volume=119 |issue=6 |pages=1637–48 |year=2000 |pmid=11113085 |doi= |url=}}</ref><ref name="pmid19575503">{{cite journal |vauthors=Assimakopoulos SF, Thomopoulos KC, Labropoulou-Karatza C |title=Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome? |journal=World J. Gastroenterol. |volume=15 |issue=25 |pages=3194–5 |year=2009 |pmid=19575503 |pmc=2705746 |doi= |url=}}</ref><ref name="pmid11113085">{{cite journal |vauthors=Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O |title=Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial |journal=Gastroenterology |volume=119 |issue=6 |pages=1637–48 |year=2000 |pmid=11113085 |doi= |url=}}</ref><ref name="pmid18164508">{{cite journal |vauthors=Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, Thévenot T, Deltenre P, Canva V, Plane C, Mathurin P |title=Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids |journal=J. Hepatol. |volume=48 |issue=3 |pages=465–70 |year=2008 |pmid=18164508 |doi=10.1016/j.jhep.2007.10.010 |url=}}</ref><ref name="pmid19340904">{{cite journal |vauthors=De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P |title=Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial |journal=World J. Gastroenterol. |volume=15 |issue=13 |pages=1613–9 |year=2009 |pmid=19340904 |pmc=2669113 |doi= |url=}}</ref><ref name="pmid19821406">{{cite journal |vauthors=Whitfield K, Rambaldi A, Wetterslev J, Gluud C |title=Pentoxifylline for alcoholic hepatitis |journal=Cochrane Database Syst Rev |volume= |issue=4 |pages=CD007339 |year=2009 |pmid=19821406 |doi=10.1002/14651858.CD007339.pub2 |url=}}</ref>
* '''Pentoxifylline'''<ref name="pmid11113085">{{cite journal |vauthors=Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O |title=Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial |journal=Gastroenterology |volume=119 |issue=6 |pages=1637–48 |year=2000 |pmid=11113085 |doi= |url=}}</ref><ref name="pmid19575503">{{cite journal |vauthors=Assimakopoulos SF, Thomopoulos KC, Labropoulou-Karatza C |title=Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome? |journal=World J. Gastroenterol. |volume=15 |issue=25 |pages=3194–5 |year=2009 |pmid=19575503 |pmc=2705746 |doi= |url=}}</ref><ref name="pmid11113085">{{cite journal |vauthors=Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O |title=Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial |journal=Gastroenterology |volume=119 |issue=6 |pages=1637–48 |year=2000 |pmid=11113085 |doi= |url=}}</ref><ref name="pmid18164508">{{cite journal |vauthors=Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, Thévenot T, Deltenre P, Canva V, Plane C, Mathurin P |title=Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids |journal=J. Hepatol. |volume=48 |issue=3 |pages=465–70 |year=2008 |pmid=18164508 |doi=10.1016/j.jhep.2007.10.010 |url=}}</ref><ref name="pmid19340904">{{cite journal |vauthors=De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P |title=Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial |journal=World J. Gastroenterol. |volume=15 |issue=13 |pages=1613–9 |year=2009 |pmid=19340904 |pmc=2669113 |doi= |url=}}</ref><ref name="pmid19821406">{{cite journal |vauthors=Whitfield K, Rambaldi A, Wetterslev J, Gluud C |title=Pentoxifylline for alcoholic hepatitis |journal=Cochrane Database Syst Rev |volume= |issue=4 |pages=CD007339 |year=2009 |pmid=19821406 |doi=10.1002/14651858.CD007339.pub2 |url=}}</ref>
**It is a [[tumor necrosis factor]] inhibitor
**It is a [[tumor necrosis factor]] inhibitor.
**Used in patients with contraindications to [[steroids]]
**Used in patients with contraindications to [[steroids]].
**Usually given for 1 months
**Usually given for 1 months.
**Decreases [[mortality]]
**Decreases [[mortality]].
**Decreases risk of [[hepatorenal syndrome]]
**Decreases risk of [[hepatorenal syndrome]].


* '''Other less commonly used drugs'''<ref name="pmid14745316">{{cite journal |vauthors=Lee TD, Sadda MR, Mendler MH, Bottiglieri T, Kanel G, Mato JM, Lu SC |title=Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis |journal=Alcohol. Clin. Exp. Res. |volume=28 |issue=1 |pages=173–81 |year=2004 |pmid=14745316 |doi=10.1097/01.ALC.0000108654.77178.03 |url=}}</ref><ref name="pmid15240996">{{cite journal |vauthors=Song Z, McClain CJ, Chen T |title=S-Adenosylmethionine protects against acetaminophen-induced hepatotoxicity in mice |journal=Pharmacology |volume=71 |issue=4 |pages=199–208 |year=2004 |pmid=15240996 |doi=10.1159/000078086 |url=}}</ref><ref name="pmid12163148">{{cite journal |vauthors=McClain CJ, Hill DB, Song Z, Chawla R, Watson WH, Chen T, Barve S |title=S-Adenosylmethionine, cytokines, and alcoholic liver disease |journal=Alcohol |volume=27 |issue=3 |pages=185–92 |year=2002 |pmid=12163148 |doi= |url=}}</ref><ref name="pmid2671116">{{cite journal |vauthors=Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B |title=Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver |journal=J. Hepatol. |volume=9 |issue=1 |pages=105–13 |year=1989 |pmid=2671116 |doi= |url=}}</ref><ref name="pmid9566830">{{cite journal |vauthors=Parés A, Planas R, Torres M, Caballería J, Viver JM, Acero D, Panés J, Rigau J, Santos J, Rodés J |title=Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial |journal=J. Hepatol. |volume=28 |issue=4 |pages=615–21 |year=1998 |pmid=9566830 |doi= |url=}}</ref>
* '''Other less commonly used drugs'''<ref name="pmid14745316">{{cite journal |vauthors=Lee TD, Sadda MR, Mendler MH, Bottiglieri T, Kanel G, Mato JM, Lu SC |title=Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis |journal=Alcohol. Clin. Exp. Res. |volume=28 |issue=1 |pages=173–81 |year=2004 |pmid=14745316 |doi=10.1097/01.ALC.0000108654.77178.03 |url=}}</ref><ref name="pmid15240996">{{cite journal |vauthors=Song Z, McClain CJ, Chen T |title=S-Adenosylmethionine protects against acetaminophen-induced hepatotoxicity in mice |journal=Pharmacology |volume=71 |issue=4 |pages=199–208 |year=2004 |pmid=15240996 |doi=10.1159/000078086 |url=}}</ref><ref name="pmid12163148">{{cite journal |vauthors=McClain CJ, Hill DB, Song Z, Chawla R, Watson WH, Chen T, Barve S |title=S-Adenosylmethionine, cytokines, and alcoholic liver disease |journal=Alcohol |volume=27 |issue=3 |pages=185–92 |year=2002 |pmid=12163148 |doi= |url=}}</ref><ref name="pmid2671116">{{cite journal |vauthors=Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B |title=Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver |journal=J. Hepatol. |volume=9 |issue=1 |pages=105–13 |year=1989 |pmid=2671116 |doi= |url=}}</ref><ref name="pmid9566830">{{cite journal |vauthors=Parés A, Planas R, Torres M, Caballería J, Viver JM, Acero D, Panés J, Rigau J, Santos J, Rodés J |title=Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial |journal=J. Hepatol. |volume=28 |issue=4 |pages=615–21 |year=1998 |pmid=9566830 |doi= |url=}}</ref>


**[[S-Adenosyl methionine|S-adenosylmethionine]]
:*[[S-Adenosyl methionine|S-adenosylmethionine]].
**Silymarin ([[silybum marianum]]-[[milk thistle]])
:*Silymarin ([[silybum marianum]]-[[milk thistle]]).


==2010 AASLD/ACG Alcoholic Liver Disease Guidelines (DO NOT EDIT)<ref name="urlwww.aasld.org">{{cite web |url=http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/AlcoholicLiverDisease1-2010.pdf |title=www.aasld.org |format= |work= |accessdate=2012-10-27}}</ref>==
==2010 AASLD/ACG Alcoholic Liver Disease Guidelines (DO NOT EDIT)<ref name="urlwww.aasld.org">{{cite web |url=http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/AlcoholicLiverDisease1-2010.pdf |title=www.aasld.org |format= |work= |accessdate=2012-10-27}}</ref>==
Line 92: Line 92:
==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WS}}
{{WH}}


[[Category:Surgery]]
[[Category:Gastroenterology]]
[[Category:Gastroenterology]]
[[Category:Up-To-Date]]
[[Category:Hepatology]]
[[Category:Hepatology]]
 
[[Category:Medicine]]
{{WS}}
{{WH}}

Latest revision as of 20:20, 29 July 2020

Alcoholic liver disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Alcoholic liver disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alcoholic liver disease medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Alcoholic liver disease medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alcoholic liver disease medical therapy

CDC on Alcoholic liver disease medical therapy

Alcoholic liver disease medical therapy in the news

Blogs on Alcoholic liver disease medical therapy

Directions to Hospitals Treating Alcoholic liver disease

Risk calculators and risk factors for Alcoholic liver disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2] Aditya Govindavarjhulla, M.B.B.S. [3]

Overview

The most important part of treatment is to stop using alcohol completely. If liver cirrhosis has not yet occurred, the liver can heal if you stop drinking alcohol. An alcohol rehabilitation program or counseling may be necessary to break the alcohol addiction. Vitamins, especially B-complex and folic acid, can help reverse malnutrition. If cirrhosis develops, there is a need to manage the complications of cirrhosis. It may need a liver transplant.

Medical therapy

General Therapy

General therapy for alcoholic liver disease includes:[1][2][3][4][5][6][7][8][9][10][11][12][13][14]

Pharmacotherapy

Alcoholic hepatitis

2010 AASLD/ACG Alcoholic Liver Disease Guidelines (DO NOT EDIT)[33]

Abstinence (DO NOT EDIT)[33]

Class I
1. " In patients with evidence of alcohol-induced liver disease, strict abstinence must be recommended, because continued alcohol use is associated with disease progression.(Level of evidence: B) "
2. " Naltrexone or acamprosate may be considered in combination with counseling to decrease the likelihood of relapse in patients with alcohol abuse/dependence in those who achieve abstinence. (Level of evidence: A) "

Treatment of Alcohol Hepatitis (DO NOT EDIT)[33]

Class I
1. " All patients with alcoholic hepatitis should be counseled to completely abstain from alcohol. (Level of evidence: B) "
2." All patients with alcoholic hepatitis or advanced ALD should be assessed for nutritional deficiencies (protein-calorie malnutrition), as well as vitamin and mineral deficiencies. Those with severe disease should be treated aggressively with enteral nutritional therapy.(Level of evidence: B)"
3." Patients with severe disease (MDF score of >32, with or without hepatic encephalopathy) and lacking contraindications to steroid use should be considered for a four week course of prednisolone (40 mg/day for 28 days, typically followed by discontinuation or a 2-week taper).(Level of evidence: A)"
4." Patients with severe disease (i.e., a MDF >32) could be considered for pentoxifylline therapy (400 mg orally 3 times daily for 4 weeks), especially if there are contraindications to steroid therapy.(Level of evidence: B)"
Class III (No Benefit)
1. " Patients with mild-moderate alcoholic hepatitis—defined as a Maddrey score of <32, without hepatic encephalopathy, and with improvement in serum bilirubin or decline in the MDF during the first week of hospitalization—should be monitored closely, but will likely not require nor benefit from specific medical interventions other than nutritional support and abstinence.(Level of evidence: A)"

Long-term Management (DO NOT EDIT)[33]

Class I
1." Patients with alcoholic cirrhosis should receive frequent interval feedings, emphasizing a night time snack and morning feeding, to improve nitrogen balance. (Level of evidence: B) "
Class III (No Benefit)
1. "Propylthiouracil (PTU) and colchicine should not be used in the treatment of patients with ALD; S-adenosyl L-methionine (SAMe) should be used only in clinical trials.(Level of evidence: A)"
2. "The use of complementary or alternative medicines in the treatment of either acute or chronic alcohol-related liver disease has shown no convincing benefit and should not be used out of the context of clinical trial.(Level of evidence: A)"

References

  1. ↑ Sofair AN, Barry V, Manos MM, Thomas A, Zaman A, Terrault NA, Murphy RC, Stabach N, Huie S, Van Ness G, Bell BP, Bialek S (2010). "The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from population-based surveillance". J. Clin. Gastroenterol. 44 (4): 301–7. doi:10.1097/MCG.0b013e3181b3f760. PMID 19745759.
  2. ↑ Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B (2009). "Deaths: final data for 2006". Natl Vital Stat Rep. 57 (14): 1–134. PMID 19788058.
  3. ↑ Kaner EF, Dickinson HO, Beyer F, Pienaar E, Schlesinger C, Campbell F, Saunders JB, Burnand B, Heather N (2009). "The effectiveness of brief alcohol interventions in primary care settings: a systematic review". Drug Alcohol Rev. 28 (3): 301–23. doi:10.1111/j.1465-3362.2009.00071.x. PMID 19489992.
  4. ↑ Moos RH, King MJ, Patterson MA (1996). "Outcomes of residential treatment of substance abuse in hospital- and community-based programs". Psychiatr Serv. 47 (1): 68–74. doi:10.1176/ps.47.1.68. PMID 8925349.
  5. ↑ Bouza C, Angeles M, Magro A, Muñoz A, Amate JM (2004). "Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review". Addiction. 99 (7): 811–28. doi:10.1111/j.1360-0443.2004.00763.x. PMID 15200577.
  6. ↑ Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT (1999). "Pharmacological treatment of alcohol dependence: a review of the evidence". JAMA. 281 (14): 1318–25. PMID 10208148.
  7. ↑ Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM (2009). "Review of topiramate: an antiepileptic for the treatment of alcohol dependence". Curr Drug Abuse Rev. 2 (2): 135–42. PMID 19630744.
  8. ↑ Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G (2007). "Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study". Lancet. 370 (9603): 1915–22. doi:10.1016/S0140-6736(07)61814-5. PMID 18068515.
  9. ↑ Corrao G, Lepore AR, Torchio P, Valenti M, Galatola G, D'Amicis A, Aricó S, di Orio F (1994). "The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Provincial Group for the Study of Chronic Liver Disease". Eur. J. Epidemiol. 10 (6): 657–64. PMID 7672043.
  10. ↑ Klatsky AL, Armstrong MA (1992). "Alcohol, smoking, coffee, and cirrhosis". Am. J. Epidemiol. 136 (10): 1248–57. PMID 1476147.
  11. ↑ Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC (1997). "Excess weight risk factor for alcoholic liver disease". Hepatology. 25 (1): 108–11. doi:10.1002/hep.510250120. PMID 8985274.
  12. ↑ Halsted CH (2004). "Nutrition and alcoholic liver disease". Semin. Liver Dis. 24 (3): 289–304. doi:10.1055/s-2004-832941. PMID 15349806.
  13. ↑ Kang YJ, Zhou Z (2005). "Zinc prevention and treatment of alcoholic liver disease". Mol. Aspects Med. 26 (4–5): 391–404. doi:10.1016/j.mam.2005.07.002. PMID 16099027.
  14. ↑ McCullough AJ, O'Connor JF (1998). "Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology". Am. J. Gastroenterol. 93 (11): 2022–36. doi:10.1111/j.1572-0241.1998.00587.x. PMID 9820369.
  15. ↑ Addolorato G, Russell M, Albano E, Haber PS, Wands JR, Leggio L (2009). "Understanding and treating patients with alcoholic cirrhosis: an update". Alcohol. Clin. Exp. Res. 33 (7): 1136–44. doi:10.1111/j.1530-0277.2009.00956.x. PMID 19389182.
  16. ↑ Christensen E (2002). "Alcoholic hepatitis--glucocorticosteroids or not?". J. Hepatol. 36 (4): 547–8. PMID 11943428.
  17. ↑ Ramond MJ, Poynard T, Rueff B, Mathurin P, Théodore C, Chaput JC, Benhamou JP (1992). "A randomized trial of prednisolone in patients with severe alcoholic hepatitis". N. Engl. J. Med. 326 (8): 507–12. doi:10.1056/NEJM199202203260802. PMID 1531090.
  18. ↑ Carithers RL, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, Maddrey WC (1989). "Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial". Ann. Intern. Med. 110 (9): 685–90. PMID 2648927.
  19. ↑ Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI (1978). "Corticosteroid therapy of alcoholic hepatitis". Gastroenterology. 75 (2): 193–9. PMID 352788.
  20. ↑ Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C (2008). "Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials". Aliment. Pharmacol. Ther. 27 (12): 1167–78. doi:10.1111/j.1365-2036.2008.03685.x. PMID 18363896.
  21. ↑ O'Shea R, McCullough AJ (2006). "Steroids or cocktails for alcoholic hepatitis". J. Hepatol. 44 (4): 633–6. doi:10.1016/j.jhep.2006.01.011. PMID 16503078.
  22. ↑ "LilleModel".
  23. ↑ 23.0 23.1 Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O (2000). "Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial". Gastroenterology. 119 (6): 1637–48. PMID 11113085.
  24. ↑ Assimakopoulos SF, Thomopoulos KC, Labropoulou-Karatza C (2009). "Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome?". World J. Gastroenterol. 15 (25): 3194–5. PMC 2705746. PMID 19575503.
  25. ↑ Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, Thévenot T, Deltenre P, Canva V, Plane C, Mathurin P (2008). "Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids". J. Hepatol. 48 (3): 465–70. doi:10.1016/j.jhep.2007.10.010. PMID 18164508.
  26. ↑ De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P (2009). "Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial". World J. Gastroenterol. 15 (13): 1613–9. PMC 2669113. PMID 19340904.
  27. ↑ Whitfield K, Rambaldi A, Wetterslev J, Gluud C (2009). "Pentoxifylline for alcoholic hepatitis". Cochrane Database Syst Rev (4): CD007339. doi:10.1002/14651858.CD007339.pub2. PMID 19821406.
  28. ↑ Lee TD, Sadda MR, Mendler MH, Bottiglieri T, Kanel G, Mato JM, Lu SC (2004). "Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis". Alcohol. Clin. Exp. Res. 28 (1): 173–81. doi:10.1097/01.ALC.0000108654.77178.03. PMID 14745316.
  29. ↑ Song Z, McClain CJ, Chen T (2004). "S-Adenosylmethionine protects against acetaminophen-induced hepatotoxicity in mice". Pharmacology. 71 (4): 199–208. doi:10.1159/000078086. PMID 15240996.
  30. ↑ McClain CJ, Hill DB, Song Z, Chawla R, Watson WH, Chen T, Barve S (2002). "S-Adenosylmethionine, cytokines, and alcoholic liver disease". Alcohol. 27 (3): 185–92. PMID 12163148.
  31. ↑ Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B (1989). "Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver". J. Hepatol. 9 (1): 105–13. PMID 2671116.
  32. ↑ Parés A, Planas R, Torres M, Caballería J, Viver JM, Acero D, Panés J, Rigau J, Santos J, Rodés J (1998). "Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial". J. Hepatol. 28 (4): 615–21. PMID 9566830.
  33. ↑ 33.0 33.1 33.2 33.3 "www.aasld.org" (PDF). Retrieved 2012-10-27.

Template:WS Template:WH

Retrieved from "https://www.wikidoc.org/index.php?title=Alcoholic_liver_disease_medical_therapy&oldid=1634488"